Avis Budget Group, Inc. (CAR)
Avis Budget (CAR) Surges 11.6%: Is This an Indication of Further Gains?
Avis Budget (CAR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Avis Budget Group Stock Was Stalling This Week
The auto industry is currently in a state of nervous anticipation, and that's not good for associated companies. One striking case in point is auto rental mainstay Avis Budget Group (CAR -11.41%), whose share price according to data compiled by S&P Global Market Intelligence was down by more than 25% week to date as of early Friday morning.
Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy
Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately 3 years, alleviating immediate financial concerns. The company faces significant competition in the CD19 CAR T-cell therapy market, making sales execution crucial for success.
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
Hemogenyx shares jump 13% as first-in-human trial of CAR-T therapy begins
Shares in Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) surged 13% in the first hour of trading after the company announced it had administered the first human dose of its experimental CAR-T cell therapy, HG-CT-1. The treatment is designed for adults with relapsed or treatment-resistant acute myeloid leukaemia, a condition with few options and a poor prognosis.
Disount To Net Cash For A Promising CAR-T Company
Galapagos NV announced a strategic split with Gilead Sciences, creating 'New Galapagos' and 'SpinCo', aiming to unlock shareholder value and reduce staffing by 40%. 'New Galapagos' will focus on cell therapies and small molecules, while 'SpinCo' will target oncology, immunology, and virology with €2.45 billion in capital. Despite an 18% share decline post-announcement, the split offers deep value and potential catalysts, though risks include governance concerns, competitive CAR-T space, and executional challenges.
Canadian Apartments: You Have To Step Up To Buy Here
CAPREIT reported strong Q4-2024 results. Notable items included a 3% distribution hike and a very substantial buyback. We go over the results and tell you why we are upgrading to a strong buy.
Avis Budget Stock Price Decreases 7% Since Reporting Loss in Q4
CAR's top line in the fourth quarter of 2024 takes a hit as revenues in the Americas decline.
Avis Budget Group, Inc. (CAR) Q4 2024 Earnings Call Transcript
Avis Budget Group, Inc. (NASDAQ:CAR ) Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants David Calabria - SVP, Corporate Finance and Treasurer Joseph Ferraro - President and CEO Izilda Martins - EVP and CFO Brian Choi - Executive VP and Chief Transformation Officer Conference Call Participants John Babcock - Bank of America Christopher Stathoulopoulos - Susquehanna Financial Harold Antor - Jefferies Jash Patwa - J.P. Morgan Chase Dan Levy - Barclays Bank Chris Woronka - Deutsche Bank Operator Greetings, and welcome to the Avis Budget Group's Fourth Quarter and Full Year 2024 Conference Call.
Avis Budget (CAR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Avis Budget (CAR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Avis Budget Group (CAR) Reports Q4 Loss, Misses Revenue Estimates
Avis Budget Group (CAR) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to earnings of $7.10 per share a year ago.
5 Broker-Favorite Stocks to Keep an Eye on Amid Current Volatility
Investors should keep a tab on stocks like General Motors, Dana, Valero Energy, National Vision and Avis Budget for high returns.
